10. Xác định hiệu quả kháng khuẩn của ceftolozane/tazobactam với các chủng Pseudomonas aeruginosa tại Bệnh viện Bạch Mai
Nội dung chính của bài viết
Tóm tắt
104 chủng P. aeruginosa phân lập tại Bệnh viện Bạch Mai trong năm 2020 đến 2021 được tiến hành xác định hiệu quả kháng khuẩn với ceftolozane/tazobactam bằng phương pháp Etest. Giá trị MIC của ceftolozane/tazobactam nằm trong khoảng từ 0,25 µg/ml đến 256 µg/ml. Mức độ nhạy cảm của vi khuẩn P. aeruginosa với ceftolozane/tazobactam là 63%, MIC50 là 0,5 µg/ml và MIC90 là 256 µg/ml. Độ nhạy cảm với ceftolozane/tazobactam của các chủng P. aeruginosa kháng carbapenem do sinh carbapenemase là 18% và không sinh carbapenemase là 71%.
Chi tiết bài viết
Từ khóa
P. aeruginosa, ceftolozane/tazobactam
Tài liệu tham khảo
1. Phạm Hồng Nhung. Tình hình đề kháng kháng sinh của Klebsiella pneumoniae, Pseudomonas aeruginosa và Acinetobacter baumannii phân lập tại khoa Hồi sức tích cực và Trung tâm Hô hấp Bệnh viện Bạch Mai giai đoạn 2012-2016. Y học Lâm sàng. 2018;101:43-51
2.. Robert A Bonomo, Dora Szabo. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis. 2006;43:S49-56. doi: 10.1086/504477
3.. Juan C, Zamorano L, Pérez JL, et al. Activity of a New Antipseudomonal Cephalosporin, CXA-101 (FR264205), against Carbapenem-Resistant and Multidrug-Resistant Pseudomonas aeruginosa Clinical Strains. Antimicrob Agents Chemother. 2010;54(2):846-851. doi: 10.1128/AAC.00834-09
4.. Hong MC, Hsu DI, Bounthavong M. Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination. Infect Drug Resist. 2013;6:215-223. doi: 10.2147/IDR.S36140
5.. Wi YM, Greenwood-Quaintance KE, Schuetz AN, et al. Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms. Antimicrob Agents Chemother. 2017;62(1). doi: 10.1128/AAC.01970-17
6. Medscape. Zerbaxa (ceftolozane/tazobactam) dosing, indications, interactions, adverse effects, and more. Accessed May 13, 2023. https://reference.medscape.com/drug/zerbaxa-ceftolozane-tazobactam-999969
7. Clinical & Laboratory Standards Institute. CLSI M100 Ed30 Performance Standards for Antimicrobial Susceptibility Testing. https://clsi.org/standards/products/microbiology/documents/m100/
8. SibylleH.Lob. In vitro activity of ceftolozane/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries-SMART 2017-2019. J Glob Antimicrob Resist. 2022;29:527-533. doi:10.1016/j.jgar.2021.11.011
9. Pfaller M, Shortridge D, Chen WT, et al. Ceftolozane/Tazobactam Activity Against Drug-Resistant Pseudomonas aeruginosa and Enterobacterales Causing Healthcare-Associated Infections in Eight Asian Countries: Report from an Antimicrobial Surveillance Program (2016-2018). Infect Drug Resist. 2022;15:6739-6753. doi:10.2147/IDR.S387097
10. Lee YL, Ko WC, Hsueh PR. Geographic Patterns of Carbapenem-Resistant Pseudomonas aeruginosa in the Asia-Pacific Region: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) Program, 2015–2019. Antimicrob Agents Chemother. 66(2):e02000-21. doi:10.1128/AAC.02000-21
11. Nguyễn Thị Thanh Mai. Phenotypic prevalence of resistance to carbapenems, colistin and genes encoding carbapenemase in Pseudomonas aeruginosa. MedPharmRes. 2021;5(1):18-22.
12. Meletis G. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis. 2016;3(1):15-21. doi:10.1177/2049936115621709
2.. Robert A Bonomo, Dora Szabo. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis. 2006;43:S49-56. doi: 10.1086/504477
3.. Juan C, Zamorano L, Pérez JL, et al. Activity of a New Antipseudomonal Cephalosporin, CXA-101 (FR264205), against Carbapenem-Resistant and Multidrug-Resistant Pseudomonas aeruginosa Clinical Strains. Antimicrob Agents Chemother. 2010;54(2):846-851. doi: 10.1128/AAC.00834-09
4.. Hong MC, Hsu DI, Bounthavong M. Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination. Infect Drug Resist. 2013;6:215-223. doi: 10.2147/IDR.S36140
5.. Wi YM, Greenwood-Quaintance KE, Schuetz AN, et al. Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms. Antimicrob Agents Chemother. 2017;62(1). doi: 10.1128/AAC.01970-17
6. Medscape. Zerbaxa (ceftolozane/tazobactam) dosing, indications, interactions, adverse effects, and more. Accessed May 13, 2023. https://reference.medscape.com/drug/zerbaxa-ceftolozane-tazobactam-999969
7. Clinical & Laboratory Standards Institute. CLSI M100 Ed30 Performance Standards for Antimicrobial Susceptibility Testing. https://clsi.org/standards/products/microbiology/documents/m100/
8. SibylleH.Lob. In vitro activity of ceftolozane/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries-SMART 2017-2019. J Glob Antimicrob Resist. 2022;29:527-533. doi:10.1016/j.jgar.2021.11.011
9. Pfaller M, Shortridge D, Chen WT, et al. Ceftolozane/Tazobactam Activity Against Drug-Resistant Pseudomonas aeruginosa and Enterobacterales Causing Healthcare-Associated Infections in Eight Asian Countries: Report from an Antimicrobial Surveillance Program (2016-2018). Infect Drug Resist. 2022;15:6739-6753. doi:10.2147/IDR.S387097
10. Lee YL, Ko WC, Hsueh PR. Geographic Patterns of Carbapenem-Resistant Pseudomonas aeruginosa in the Asia-Pacific Region: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) Program, 2015–2019. Antimicrob Agents Chemother. 66(2):e02000-21. doi:10.1128/AAC.02000-21
11. Nguyễn Thị Thanh Mai. Phenotypic prevalence of resistance to carbapenems, colistin and genes encoding carbapenemase in Pseudomonas aeruginosa. MedPharmRes. 2021;5(1):18-22.
12. Meletis G. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis. 2016;3(1):15-21. doi:10.1177/2049936115621709